Andrea Cesari: Comparing Catheter-Based Reperfusion Strategies for Intermediate-High-Risk PE
Andrea Cesari, Cardiologist at Niguarda Hospital, Milan, shared post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of Clinical Medicine, adding:
“I am pleased to share our recent multicenter study evaluating catheter-based reperfusion strategies in patients with intermediate-high-risk acute pulmonary embolism (PE).
In the ‘USAT IH-PE‘ registry, we compared ultrasound-assisted catheter-directed thrombolysis (USAT) and mechanical thrombectomy (MT) in a real-world cohort of patients treated during the acute phase of PE.
After propensity-score matching, both approaches were associated with significant improvements in RV function and pulmonary hemodynamics, with comparable 30-day mortality outcomes and low rates of major bleeding.
These findings contribute to the growing body of evidence supporting catheter-based therapies in selected patients with intermediate-high-risk PE, while emphasizing the importance of individualized treatment decisions in contemporary practice.”
Elena Gualini, Cardiologist at Niguarda Hospital, Milan, shared Andrea Cesari‘s post on LinkedIn:
“Happy to share our latest publication, providing real-world evidence on catheter-directed therapies for intermediate-high-risk pulmonary embolism”
Title: Comparative Outcomes of Ultrasound-Assisted Thrombolysis and Mechanical Thrombectomy in Intermediate-High-Risk Pulmonary Embolism
Authors: Claudia Colombo, Marco Zuin, Filippo Russo, Mario Iannaccone, Marco Solcia, Francesco Musca, Ilaria Emanuela Bossi, Andrea Cesari, Elena Gualini, Federica Fumarola, Alberto Balderi, Francesca Giordana, Andrea Discalzi, Lorenzo Tua, Stefano Buratti, Ruggero Vercelli, Lorenzo Cianfanelli, Marianna Adamo, Alaide Chieffo, Giacomo Bocuzzi, Matteo Montorfano, Fabrizio Oliva, Alice Sacco

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering